Exclusive Summary

• Tenofovir alafenamide Fumarate (TAF) is a globally recommended first-line treatment for HBV, ensuring stable market demand and offering effective alternatives or complements to existing therapies.
• The TAF generic market is experiencing growth as originator patents expire, positioning Chinese suppliers with cost advantages and robust MAA capabilities to capture significant market share.
• TAF offers superior renal and bone safety profiles compared to older generation TDF, making it a preferred choice for HBV patients worldwide and providing a significant competitive edge.
• Leveraging large-scale production, international certifications (e.g., cGMP), and extensive registration experience, our TAF generics can deliver high-quality, cost-effective solutions to global markets.
• Given the widespread and ongoing need for HBV treatment, TAF's promotion will make innovative and affordable therapeutic options accessible to more patients, ensuring sustained market potential.